Ciechanowicz A, Kawiak J, Miks B, Dutkiewicz T, Długosz A, Syczewska-Wawrzynowicz M, Marzecka J
Department of Clinical Biochemistry, Pomeranian Academy of Medicine, Szczecin, Poland.
Ann Clin Biochem. 1993 Sep;30 ( Pt 5):445-8. doi: 10.1177/000456329303000505.
The concentration of plasma prekallikrein (PK) in five patients with hepatocellular carcinoma (HCC) has been measured and related to levels in 18 patients with liver cirrhosis (LC) and 30 healthy subjects. It was found that the mean PK level was significantly increased in patients with HCC, while patients with LC demonstrated lower concentrations, as compared with healthy subjects. The results indicate that PK might be useful in screening cirrhotic patients for HCC. Longitudinal studies of PK in a larger group of patients at risk of developing HCC are therefore recommended.
已对5例肝细胞癌（HCC）患者的血浆前激肽释放酶（PK）浓度进行了测量，并与18例肝硬化（LC）患者和30名健康受试者的水平进行了关联。结果发现，HCC患者的平均PK水平显著升高，而LC患者的浓度低于健康受试者。结果表明，PK可能有助于对肝硬化患者进行HCC筛查。因此，建议对更多有发生HCC风险的患者进行PK的纵向研究。
